In-silico study reveals potential antitubercular drug targets unique to Mycobacterium tuberculosis H37Rv


Maurya S., Alhazmi A., Vidyarthi A. S. , Jain A., Singh V., Khan F., ...More

MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH, vol.34, no.2, pp.71-79, 2022 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.23736/s2724-542x.21.02849-2
  • Title of Journal : MINERVA BIOTECHNOLOGY AND BIOMOLECULAR RESEARCH
  • Page Numbers: pp.71-79
  • Keywords: Mycobacterium tuberculosis, Proteome, Genes, essential, Gene ontology, IDENTIFICATION

Abstract

BACKGROUND: Developing safe drugs for tuberculosis (TB), is a major challenge due to upsurge in drug resistance, hepatotoxicity, and the presence of Mycobacterium tuberculosis (Mtb) targets orthologs in human and its non-pathogenic host E. coli. Prostaglandin G/H synthase-2 and 30S ribosomal-S12 protein of Mtb show 100 and 48% similarity with human proteins respectively. Thus, targeting these Mtb proteins by p-aminosalicylic acid and streptomycin for the treatment of TB adversely affect human metabolism, and warrants to identify novel and unique drug targets of Mtb.